SWOG clinical trial number
SWOG-8896

Phase III Protocol for Surgical Adjuvant Therapy of Rectal Carcinoma: A Controlled Evaluation of A. Protracted Infusion 5-Fluorouracil as a Radiation Enhancer and B. 5-FU Plus Methyl-CCNU Chemotherapy

Closed
Phase
Published
Abbreviated Title
RECTAL
Activated
09/15/1988
Closed
09/01/1990
Participants
NCORP, Members, Medical Oncologists, Radiation Oncologists, Surgeons

Research committees

Gastrointestinal Cancer

Treatment

5-Fluorouracil Methyl-CCNU

Publication Information Expand/Collapse

1994

Improved adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery

MJ O'Connell;JA Martenson;HS Wieand;JE Krook;JS Macdonald;DG Haller;RJ Mayer;LL Gunderson;TA Rich New England Journal of Medicine 331(8):502-507

1993

Protracted venous infusion (PVI) 5-fluorouracil (5-FU) as a component of effective combined modality post-operative surgical adjuvant therapy for high-risk rectal cancer.

M O'Connell;J Martenson;T Rich;H Wieand;J Krook;J Macdonald;D Haller;R Mayer;L Gunderson ASCO 12:193(#564)

1991

Lack of value for metyl-CCNU (MeCCNU) as a component of effective rectal cancer surgical adjuvant therapy. Interim analysis of intergroup protocol 86-47-51.

M O'Connell;H Wieand;J Krook;J Martenson;J Macdonald;T Rich;D Haller;R Mayer;L Gunderson ASCO 10:134(#403)

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
100%
Open
Phase